All Pharmaceutical Microbiology articles – Page 20
-
News Crowd-sourced potent SARS-CoV-2 antiviral lead compound announced by COVID Moonshot Consortium
More than 200 scientists and students, triggered by a Twitter appeal, have identified and developed novel compounds with excellent antiviral activity against a key enzyme of the SARS-COV-2 virus, the main protease (Mpro).
-
NewsResearchers discover new method to inhibit cholera infection
A new study investigates a novel strategy for inhibiting the spread and infection of Vibrio cholerae, the bacteria responsible for the disease cholera.
-
NewsUK lagging on availability of treatment for rare diseases, industry group warns
A group of companies developing innovative new medicines for rare diseases is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice to improve access to new treatments for patients.
-
NewsDrugs targeting iron regulation could be the answer to antifungal resistance
Drugs targeting iron uptake mechanisms could prove vital in the fight against human fungal pathogens, a new review suggests.
-
NewsBroad-spectrum antiviral candidate targets dengue and SARS-CoV-2
A broad-spectrum antiviral drug candidate, 2-thiouridine, that targets positive-strand RNA viruses has been identified and characterized.
-
NewsTechnique restores the function of a human cell surface protein in yeast cells
Scientists report a technique that could promote the use of yeast as a convenient platform to study human proteins and develop new drugs.
-
NewsGut microbiota-derived 7-DHC tackles circadian rhythm disorders and IBD
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract categorized into ulcerative colitis and Crohn’s disease. Currently, aminosalicylates, glucocorticoids, immunomodulating drugs, and biological agents are common strategies for the treatment of IBD. The efficacy of these therapies is limited, however, and they are ...
-
News‘Subway map’ of Lyme disease pathways IDs potential treatment targets
Researchers have developed a genome-scale metabolic model of key metabolic activities of the bacterium that causes Lyme disease, successfully identifying two compounds that selectively target routes only used by Lyme disease to infect a host.
-
NewsYeast speeds discovery of medicinal compounds in plants
Researchers have harnessed the power of baker’s yeast to create a cost-effective and highly efficient approach for unraveling how plants synthesize medicinal compounds, and used the new method to identify key enzymes in a kratom tree.
-
NewsResearchers probe >10,000 drug combinations to beat AMR
In an extensive investigation, researchers have tested over 10,000 drug combinations against some of the leading pathogenic bacteria carrying antimicrobial resistance and causing mortality.
-
NewsAlert immune system in respiratory tract protects children from severe Covid
Scientists have discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.
-
NewsNovel enzyme family could provide insights into bacterial pathogenicity
Researchers discover a new family of Gram-negative bacterial enzymes related to infection capability.
-
News‘Remarkable’ medical discovery for sepsis moves to next phase of human trials
Florey researchers, working with hospital intensive care clinicians, have shown that sodium ascorbate – a pH-balanced formulation of vitamin C – is effective in treating sepsis.
-
NewsNovel biomaterial delivers medication directly to fish gut
In addition to helping combat antimicrobial resistance, the bioparticle avoids the waste and pollution created by excessive amounts of drugs in water bodies.
-
NewsStudy IDs six drugs that can be repurposed for treatment of toxoplasmosis
Brazilian researchers screened 160 compounds known to be effective against SARS-CoV-2 and identified those that also act against the protozoan parasite Toxoplasma gondii.
-
NewsResearchers developing an oral therapeutic to treat drug-resistant bacterial pneumonia
Australian researchers aim to rescue common antibiotics with a new therapeutic approach, using a drug originally developed to treat neurodegenerative disorders.
-
NewsVersatile vaccine candidate fights measles, mumps and Covid
Altered measles and mumps viruses could be used as a platform to create a trivalent COVID-19 vaccine that triggers immunity to multiple variant strains of the SARS-CoV-2 virus, new research in animals suggests. The study builds upon previous studies that involved inserting a highly stable segment of ...
-
NewsSRI spins off AI-powered drug discovery platform Synfini, Inc
SRI International has announced it is spinning off Synfini, a biosciences platform that accelerates the process by which pharmaceutical and other companies can design, synthesize, and bring to market molecules for drug development.
-
NewsAntibiotics can help some bacteria survive for longer
Scientists have found a surprising effect of some antibiotics on certain bacteria – that the drugs can sometimes benefit bacteria, helping them live longer.
-
NewsResearchers pioneer safe chemotherapy methods for treating bacterial infections
Antibiotic resistant bacteria are a threat to human lives, and yet the development of new drugs to treat bacterial infections is slow. A group of proven drugs used in cancer treatment for decades could possibly be the solution. A new class of antibiotics is now being developed by researchers at ...